NMDA receptors in nervous system diseases

Neuropharmacology

Volumn 74, Issue , 2013, Pages 69-75

  Zhou, Qiang ^a   Sheng, Morgan ^a  

^a GENENTECH INC   (United States)

Author keywords

Glutamate; Neurodegeneration; Synaptic plasticity; Synaptic transmission

Indexed keywords

ANTIDEPRESSANT AGENT; DEXTRO SERINE; GLYCINE; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; SEROTONIN UPTAKE INHIBITOR;

ALZHEIMER DISEASE; BRAIN INFARCTION; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; DEGENERATIVE DISEASE; DEPRESSION; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; INTERNEURON; LOW DRUG DOSE; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SUBUNIT; REVIEW; SCHIZOPHRENIA; SYNAPSE; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT;

GLUTAMATE; NEURODEGENERATION; SYNAPTIC PLASTICITY; SYNAPTIC TRANSMISSION;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MODELS, NEUROLOGICAL; PROTEIN SUBUNITS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84885174557     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.03.030     Document Type: Review

References (101)

1. Aarts, M., Liu, Y., Liu, L., Besshoh, S., Arundine, M., Gurd, J.W., Wang, Y.T., Salter, M.W., Tymianski, M., 2002. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 298 (5594), 846-850.
2. Abe, T., Matsumura, S., Katano, T., Mabuchi, T., Takagi, K., Xu, L, Yamamoto, A., Hattori, K., Yagi, T., Watanabe, M., Nakazawa, T., Yamamoto, T., Mishina, M., Nakai, Y, Ito, S., 2005. Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain. Eur. J. Neurosci. 22 (6), 1445-1454.
3. Al-Hallaq, R.A., Conrads, T.P., Veenstra, T.D., Wenthold, R.J., 2007. NMDA diheteromeric receptor populations and associated proteins in rat hippocampus. J. Neurosci. 27 (31), 8334-8343.
4. Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., Kavalali, E.T., Monteggia, L.M., 2011. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (7354), 91-95.
5. Beauchamp, K., Mutlak, H., Smith, W.R., Shohami, E., Stahel, P.F., 2008. Pharmacology of traumatic brain injury: where is the "golden bullet"? Mol. Med. 14 (11-12), 731-740.
6. Belforte, J.E., Zsiros, V., Sklar, E.R., Jiang, Z., Yu, G., Li, Y, Quinlan, E.M., Nakazawa, K., 2010. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 13 (1), 76-83.
7. Berberich, S., Punnakkal, P., Jensen, V., Pawlak, V., Seeburg, P.H., Hvalby, Ø., Köhr, G., 2005. Lack of NMDA receptor subtype selectivity for hippocampal long-term potentiation. J. Neurosci. 25 (29), 6907-6910.
8. Berman, R.M., Cappiello, A., Anand, A., Oren, DA, Heninger, G.R., Charney, D.S., Krystal, J.H., 2000. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47 (4), 351-354.
9. Biegon, A., Fry, P.A., Paden, CM., Alexandrovich, A., Tsenter, J., Shohami, E., 2004. Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: implications for treatment of neurological and cognitive deficits. Proc. Natl. Acad. Sci. U. S. A. 101 (14), 5117-5122.
10. Bitanihirwe, B.K., Lim, M.P., Kelley, J.F., Kaneko, T., Woo, T.U., 2009. Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. BMC Psychiatry 9, 71.
11. Bordji, K., Becerril-Ortega, J., Nicole, O., Buisson, A., 2010. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-β production. J. Neurosci. 30 (47), 15927-15942.
12. Boyce, S., Wyatt, A., Webb, J.K., O'Donnell, R., Mason, G., Rigby, M., Sirinathsinghji, D., Hill, R.G., Rupniak, N.M., 1999. Selective NMDA NR2B antagonists induce anti-nociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 38 (5), 611-623.
13. Bullock, R., Zauner, A., Woodward, J.J., Myseros, J., Choi, S.C., Ward, J.D., Marmarou, A., Young, H.F., 1998. Factors affecting excitatory amino acid release following severe human head injury. J. Neurosurg. 89 (4), 507-518.
14. Chen, M., Lu, T.J., Chen, X.J., Zhou, Y, Chen, Q., Feng, X.Y., Xu, L, Duan, W.H., Xiong, Z.Q., 2008. Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke 39 (11), 3042-3048.
15. Chen, M.H., Bullock, R., Graham, D.I., Miller, J.D., McCulloch, J., 1991. Ischemic neuronal damage after acute subdural hematoma in the rat: effects of pre-treatment with a glutamate antagonist. J. Neurosurg. 74 (6), 944-950.
16. Choi, D.W., 1987. Ionic dependence of glutamate neurotoxicity. J. Neurosci. 7 (2), 369-379.
17. Cook, D.J., Teves, L., Tymianski, M., 2012. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci. Transl. Med. 4 (154), 154ra133.
18. Coyle, J.T., 2006. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 26 (4-6), 365-384.
19. Cull-Candy, S.G., Leszkiewicz, D.N., 2004. Role of distinct NMDA receptor subtypes at central synapses. Sci. STKE 2004 (255), re16.
20. Deshpande, A., Kawai, H., Metherate, R., Glabe, C.G., Busciglio, J., 2009. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J. Neurosci. 29 (13), 4004-4015.
21. Frizelle, P.A., Chen, P.E., Wyllie, D.J., 2006. Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2, 3-dioxo-1,2,3, 4- tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: implications for studies of synaptic transmission. Mol. Pharmacol. 70 (3), 1022-1032.
22. Hardingham, G.E., Bading, H., 2010. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11 (10), 682-696.
23. Hardingham, G.E., Fukunaga, Y., Bading, H., 2002. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5 (5), 405-414.
24. Hatton, C.J., Paoletti, P., 2005. Modulation of triheteromeric NMDA receptors by N-terminal domain ligands. Neuron 46 (2), 261-274.
25. Heng, M.Y., Detloff, P.J., Wang, P.L., Tsien, J.Z., Albin, R.L., 2009. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J. Neurosci. 29 (10), 3200-3205.
26. Hetman, M., Kharebava, G., 2006. Survival signaling pathways activated by NMDA receptors. Curr. Top. Med. Chem. 6 (8), 787-799.
27. Hill, M.D., Martin, R.H., Mikulis, D., Wong, J.H., Silver, F.L., Terbrugge, K.G., Milot, G., Clark, W.M., Macdonald, R.L., Kelly, M.E., Boulton, M., Fleetwood, I., McDougall, C., Gunnarsson, T., Chow, M., Lum, C., Dodd, R., Poublanc, J., Krings, T., Demchuk, A.M., Goyal, M., Anderson, R., Bishop, J., Garman, D., Tymianski, M., for the ENACT trial investigators, 2012. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 11 (11), 942-950.
28. Hoey, S.E., Williams, R.J., Perkinton, M.S., 2009. Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. J. Neurosci. 29 (14), 4442-4460.
29. Homayoun, H., Moghaddam, B., 2007. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27 (43), 11496-11500.
30. Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T.I., Stefovska, V., Turski, L., Olney, J.W., 1999. Blockade of NMDA receptors and apoptoticneurodegenerationinthedeveloping brain. Science 283 (5398), 70-74.
31. Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B.C., Christie, M.J., Napier, I.A., Eckert, A., Staufenbiel, M., Hardeman, E., Götz, J., 2010. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142 (3), 387-397.
32. Jernigan, C.S., Goswami, D.B., Austin, M.C., Iyo, A.H., Chandran, A., Stockmeier, C.A., Karolewicz, B., 2011. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 35 (7), 1774-1779.
33. Jo, J., Whitcomb, D.J., Olsen, K.M., Kerrigan, T.L., Lo, S.C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G., Cho, K., 2011. Ab(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3b. Nat. Neurosci. 14 (5), 545-547.
34. Jocoy, E.L., André, V.M., Cummings, D.M., Rao, S.P., Wu, N., Ramsey, A.J., Caron, M.G., Cepeda, C., Levine, M.S., 2011. Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-d-aspartate currents by dopamine D1 receptor activation in striatum. Front. Syst. Neurosci. 5, 28.
35. Jurado, S., Benoist, M., Lario, A., Knafo, S., Petrok, C.N., 2010. Esteban JA. PTEN is recruited to the postsynaptic terminal for NMDA receptor-dependent long-term depression. EMBO J. 29 (16), 2827-2840.
36. Karlsson, U., Sjödin, J., Angeby Möller, K., Johansson, S., Wikström, L., Näsström, J., 2002. Glutamate-induced currents reveal three functionally distinct NMDA receptor populations in rat dorsal horn - effects of peripheral nerve lesion and inflammation. Neuroscience 112 (4), 861-868.
37. Kim, M.J., Dunah, A.W., Wang, Y.T., Sheng, M., 2005. Differential roles of NR2A- and NR2B-containing NMDA receptors in Ras-ERK signaling and AMPA receptor trafficking. Neuron 46 (5), 745-760.
38. Kinney, J.W., Davis, C.N., Tabarean, I., Conti, B., Bartfai, T., Behrens, M.M., 2006. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J. Neurosci. 26 (5), 1604-1615.
39. 2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J. Neurosci. 29 (9), 2774-2779.
40. Labrie, V., Wong, A.H., Roder, J.C., 2012. Contributions of the D-serine pathway to schizophrenia. Neuropharmacology 62 (3), 1484-1503.
41. Lai, T.W., Shyu, W.C., Wang, Y.T., 2011. Stroke intervention pathways: NMDA receptors and beyond. Trends Mol. Med. 17 (5), 266-275.
42. Leonard, A.S., Lim, I.A., Hemsworth, D.E., Horne, M.C., Hell, J.W., 1999. Calcium/calmodulin-dependent protein kinase II is associated with the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U. S. A. 96 (6), 3239-3244.
43. Lewis, D.A., Curley, A.A., Glausier, J.R., Volk, D.W., 2012. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 35 (1), 57-67.
44. Lewis, D.A., Hashimoto, T., Volk, D.W., 2005. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6 (4), 312-324.
45. Li, N., Liu, R.J., Dwyer, J.M., Banasr, M., Lee, B., Son, H., Li, X.Y., Aghajanian, G., Duman, R.S., 2011a. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69 (8), 754-761.
46. Li, S., Jin, M., Koeglsperger, T., Shepardson, N.E., Shankar, G.M., Selkoe, D.J., 2011b. Soluble Ab oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 31 (18), 6627-6638.
47. Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., Duman, R.S., 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (5994), 959-964.
48. Li, S., Hong, S., Shepardson, N.E., Walsh, D.M., Shankar, G.M., Selkoe, D., 2009. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62 (6), 788-801.
49. Lindsley, C.W., Shipe, W.D., Wolkenberg, S.E., Theberge, CR., Williams Jr, D.L., Sur, C, Kinney, G.G., 2006. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. Med. Chem. 6 (8), 771-785.
50. Liu, Y., Wong, T.P., Aarts, M., Rooyakkers, A., Liu, L., Lai, T.W, Wu, D.C., Lu, J., Tymianski, M., Craig, A.M., Wang, Y.T., 2007. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 27 (11), 2846-2857.
51. Liu, J., Chang, L., Roselli, F., Almeida, O.F., Gao, X., Wang, X., Yew, D.T., Wu, Y, 2010. Amyloid-β induces caspase-dependent loss of PSD-95 and synaptophysin through NMDA receptors. J. Alzheimers Dis. 22 (2), 541-556.
52. Lucas, D.R., Newhouse, J.P., 1957. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch. Ophthalmol. 58 (2), 193-201.
53. Luo, J., Wang, Y, Yasuda, R.P., Dunah, A.W., Wolfe, B.B., 1997. The majority of N-methyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B). Mol. Pharmacol. 51 (1), 79-86.
54. Malinow, R., 2012. New developments on the role of NMDA receptors in Alzheimer's disease. Curr. Opin. Neurobiol. 22 (3), 559-563.
55. Margaill, I., Parmentier, S., Callebert, J., Allix, M., Boulu, R.G., Plotkine, M., 1996. Short therapeutic window for MK-801 in transient focal cerebral ischemia in normotensive rats. J. Cereb. Blood Flow Metab. 16 (1), 107-113.
56. Martel, M.A., Ryan, T.J., Bell, K.F., Fowler, J.H., McMahon, A., Al-Mubarak, B., Komiyama, N.H., Horsburgh, K., Kind, P.C., Grant, S.G., Wyllie, D.J., Hardingham, G.E., 2012. The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron 74 (3), 543-556.
57. Marvizón, J.C., McRoberts, J.A., Ennes, H.S., Song, B., Wang, X., Jinton, L., Corneliussen, B., Mayer, E.A., 2002. Two N-methyl-D-aspartate receptors in rat dorsal root ganglia with different subunit composition and localization. J. Comp. Neurol. 446 (4), 325-341.
58. Matsumura, S., Kunori, S., Mabuchi, T., Katano, T., Nakazawa, T., Abe, T, Watanabe, M., Yamamoto, T., Okuda-Ashitaka, E., Ito, S., 2010. Impairment of CaMKII activation and attenuation of neuropathic pain in mice lacking NR2B phosphorylated at Tyr1472. Eur. J. Neurosci. 32 (5), 798-810.
59. Milnerwood, A.J., Raymond, LA, 2010. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 33 (11), 513-523.
60. Milnerwood, A.J., Gladding, C.M., Pouladi, M.A., Kaufman, A.M., Hines, R.M., Boyd, J.D., Ko, R.W., Vasuta, O.C, Graham, R.K., Hayden, M.R., Murphy, T.H., Raymond, LA, 2010. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65 (2), 178-190.
61. Moghaddam, B., Javitt, D., 2012. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37 (1), 4-15.
62. Mohn, A.R., Gainetdinov, R.R., Caron, M.G., Koller, B.H., 1999. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (4), 427-436.
63. Monyer, H., Burnashev, N., Laurie, D.J., Sakmann, B., Seeburg, P.H., 1994. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12 (3), 529-540.
64. Nakazato, E., Kato, A., Watanabe, S., 2005. Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model. Pharmacology 73(1), 8-14.
65. Neyton, J., Paoletti, P., 2006. Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J. Neurosci. 26 (5), 1331-1333.
66. Niesters, M., Dahan, A., 2012. Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain. Expert Opin. Drug Metab. Toxicol. 8 (11), 1409-1417.
67. Nozaki, C, Vergnano, A.M., Filliol, D., Ouagazzal, A.M., Le Goff, A., Carvalho, S., Reiss, D., Gaveriaux-Ruff, C, Neyton, J., Paoletti, P., Kieffer, B.L, 2011. Zinc alleviates pain through high-affinity binding to the NMDA receptor NR2A subunit. Nat. Neurosci. 14 (8), 1017-1022.
68. Okamoto, S., Pouladi, M.A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D.E., Zaidi, R., Clemente, A., Kaul, M., Graham, R.K., Zhang, D., Vincent Chen, H.S., Tong, G., Hayden, M.R., Lipton, S.A., 2009. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 15 (12), 1407-1413.
69. Ondrejcak, T., Klyubin, I., Hu, N.W, Barry, A.E., Cullen, W.K., Rowan, M.J., 2010. Alzheimer's disease amyloid beta-protein and synaptic function. Neuromolecular Med. 12 (1), 13-26.
70. Paoletti, P., 2011. Molecular basis of NMDA receptor functional diversity. Eur. J. Neurosci. 33 (8), 1351-1365.
71. Paoletti, P., Neyton, J., 2007. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 7 (1), 39-47.
72. Papouin, T., Ladépêche, L., Ruel, J., Sacchi, S., Labasque, M., Hanini, M., Groc, L., Pollegioni, L, Mothet, J.P., Oliet, S.H., 2012. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150 (3), 633-646.
73. Pedersen, L.M., Gjerstad, J., 2008. Spinal cord long-term potentiation is attenuated by the NMDA-2B receptor antagonist Ro 25-6981. Acta Physiol. (Oxf) 192 (3), 421-427.
74. Qu, X.X., Cai, J., Li, M.J., Chi, Y.N., Liao, F.F., Liu, F.Y, Wan, Y, Han, J.S., Xing, G.G., 2009. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain. Exp. Neurol. 215 (2), 298-307.
75. Rammes, G., Hasenjäger, A., Sroka-Saidi, K., Deussing, J.M., Parsons, CG., 2011. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60 (6), 982-990.
76. Rauner, C., Köhr, G., 2011. Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses. J. Biol. Chem. 286 (9), 7558-7566.
77. Rönicke, R., Mikhaylova, M., Rönicke, S., Meinhardt, J., Schröder, U.H., Fändrich, M., Reiser, G., Kreutz, M.R., Reymann, K.G., 2011. Early neuronal dysfunction by amyloid b oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol. Aging 32 (12), 2219-2228.
78. Rothman, S.M., Olney, J.W., 1995. Excitotoxicity and the NMDA receptor - still lethal after eight years. Trends Neurosci. 18 (2), 57-58.
79. Salter, M.W., Kalia, L.V., 2004. Src kinases: a hub for NMDA receptor regulation. Nat. Rev. Neurosci. 5 (4), 317-328.
80. Sandkühler, J., 2007. Understanding LTP in pain pathways. Mol. Pain 3, 9.
81. Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., Sabatini, B.L., 2007. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27 (11), 2866-2875.
82. Sheng, M., Sabatini, B.L., Südhof, T.C., 2012. Synapses and Alzheimer's disease. Cold Spring Harb. Perspect. Biol. 4 (5).
83. Sheng, M., Kim, E., 2011. The postsynaptic organization of synapses. Cold Spring Harb. Perspect. Biol. 3 (12).
84. Sheng, M., Cummings, J., Roldan, L.A., Jan, Y.N., Jan, L.Y., 1994. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 368 (6467), 144-147.
85. Simon, R.P., Swan, J.H., Griffiths, T., Meldrum, B.S., 1984. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 226 (4676), 850-852.
86. Soriano, F.X., Martel, M.A., Papadia, S., Vaslin, A., Baxter, P., Rickman, C., Forder, J., Tymianski, M., Duncan, R., Aarts, M., Clarke, P., Wyllie, D.J., Hardingham, G.E., 2008. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J. Neurosci. 28 (42), 10696-10710.
87. Tallaksen-Greene, S.J., Janiszewska, A., Benton, K., Ruprecht, L., Albin, R.L., 2010. Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Exp. Neurol. 225 (2), 402-407.
88. Terasaki, Y., Sasaki, T., Yagita, Y., Okazaki, S., Sugiyama, Y., Oyama, N., Omura-Matsuoka, E., Sakoda, S., Kitagawa, K., 2010. Activation of NR2A receptors induces ischemic tolerance through CREB signaling. J. Cereb. Blood Flow Metab. 30 (8), 1441-1449.
89. Tovar, K.R., Westbrook, G.L., 1999. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J. Neurosci. 19 (10), 4180-4188.
90. Traynelis, S.F., Wollmuth, L.P., McBain, C.J., Menniti, F.S., Vance, K.M., Ogden, K.K., Hansen, K.B., Yuan, H., Myers, S.J., Dingledine, R., 2010. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 62 (3), 405-496.
91. Tu, W., Xu, X., Peng, L., Zhong, X., Zhang, W., Soundarapandian, M.M., Balel, C., Wang, M., Jia, N., Zhang, W., Lew, F., Chan, S.L., Chen, Y., Lu, Y., 2010. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell. 140 (2), 222-234.
92. Wang, C.C., Held, R.G., Chang, S.C., Yang, L., Delpire, E., Ghosh, A., Hall, B.J., 2011. A critical role for GluN2B-containing NMDA receptors in cortical development and function. Neuron 72 (5), 789-805.
93. Watanabe, M., Inoue, Y., Sakimura, K., Mishina, M., 1992. Developmental changes in distribution of NMDA receptor channel subunit mRNAs. Neuroreport 3 (12), 1138-1140.
94. Wei, F., Wang, G.D., Kerchner, G.A., Kim, S.J., Xu, H.M., Chen, Z.F., Zhuo, M., 2001. Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat. Neurosci. 4 (2), 164-169.
95. Weitlauf, C., Honse, Y., Auberson, Y.P., Mishina, M., Lovinger, D.M., Winder, D.G., 2005. Activation of NR2A-containing NMDA receptors is not obligatory for NMDA receptor-dependent long-term potentiation. J. Neurosci. 25 (37), 8386-8390.
96. Wilson, J.A., Garry, E.M., Anderson, H.A., Rosie, R., Colvin, L.A., Mitchell, R., Fleetwood-Walker, S.M., 2005. NMDA receptor antagonist treatment at the time of nerve injury prevents injury-induced changes in spinal NR1 and NR2B subunit expression and increases the sensitivity of residual pain behaviours to subsequently administered NMDA receptor antagonists. Pain 117 (3), 421-432.
97. Wu, L.J., Zhuo, M., 2009. Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain. Neurotherapeutics 6 (4), 693-702.
98. Xia, P., Chen, H.S., Zhang, D., Lipton, S.A., 2010. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J. Neurosci. 30 (33), 11246-11250.
99. Yang, Y., Li, Q., Yang, T., Hussain, M., Shuaib, A., 2003. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101, 606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats. J. Neurosurg. 98 (2), 397-403.
100. Zarate Jr., C.A., Singh, J., Manji, H.K., 2006. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry 59 (11), 1006-1020.
101. Zhao, M.G., Toyoda, H., Lee, Y.S., Wu, L.J., Ko, S.W., Zhang, X.H., Jia, Y., Shum, F., Xu, H., Li, B.M., Kaang, B.K., Zhuo, M., 2005. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron 47 (6), 859-872.